Stem Cell Cryopreservation Composition With Low-DMSO Thaw Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stem cell refrigerated formulations have a short shelf life of 3 to 10 days, posing distribution challenges, and existing cryopreservation methods using DMSO as a cryoprotectant raise safety concerns due to potential tissue harm at concentrations above 5%, necessitating a formulation that maintains stability and efficacy for extended storage and safe human administration.
Innovation Solution
A cryopreservation composition comprising glucose, DMSO, and human serum is developed, with specific concentration ranges to reduce DMSO content while ensuring stem cell viability, differentiation potential, and safety for long-term storage and direct human use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If DMSO concentration is reduced to improve safety, then safety is improved, but stability and efficacy of stem cells during freezing are compromised
Solution Approach 1:
The patent introduces glucose as an intermediary substance that mediates between the conflicting requirements of low DMSO concentration and high stem cell stability. Glucose acts as a cryoprotectant that works synergistically with reduced DMSO to maintain cell membrane integrity and prevent ice crystal formation, thereby preserving stem cell viability without the toxic effects of high DMSO concentrations
Solution Approach 2:
The patent changes the concentration parameters of multiple components in the cryopreservation formulation. Specifically, it optimizes glucose concentration (1-10% w/v), DMSO concentration (0.5-5% v/v), and human serum concentration (90-98% v/v) to achieve the optimal balance between safety and stability, moving away from the conventional high DMSO formulation
2Duration of action of stationary object
If shelf life is extended to improve distribution, then distribution is improved, but formulation complexity increases
Solution Approach 1:
The patent creates a composite cryopreservation formulation by combining multiple substances (glucose, DMSO, and human serum) in specific proportions. This composite approach allows the formulation to achieve extended shelf life (up to 20 years) while maintaining relative simplicity, as each component contributes a specific function: glucose for cryoprotection, DMSO for membrane stabilization, and human serum for nutrient supply and cell recognition
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition maintains stem cell viability, differentiation potential, and safety, allowing for extended storage up to 20 years and direct administration without further treatment, while reducing DMSO-related toxicity.
Implementation Method 1
Currently, the most widely used cell cryoprotectant is DMSO (dimethyl sulfoxide). DMSO is essential for freezing cells
Implementation Method 2
when glucose is added to a cryopreservation composition for stem cell therapy (cryopreservation formulation), a cryopreservation formulation with reduced DMSO content may be prepared that maintains efficacy
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a composition (frozen formulation) used for cryopreservation of stem cells, and a cryopreservation method of stem cells using the composition. According to the cryopreservation solution of stem cells and the cryopreservation method using same of the present invention, the stem cells can be preserved for a long period of time, exhibit a high survival rate after being thawed, and can be directly applied to a living body without additional treatment after thawing.